Literature DB >> 12142108

N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation.

Tomas Jernberg1, Mats Stridsberg, Per Venge, Bertil Lindahl.   

Abstract

OBJECTIVES: The study evaluated the prognostic value of single measurement of N-terminal pro brain natriuretic peptide (NT-proBNP) obtained on admission in patients with symptoms suggestive of an acute coronary syndrome and no ST-segment elevation.
BACKGROUND: Patients with symptoms suggestive of an acute coronary syndrome and no ST-segment elevation constitute a large and heterogeneous population. Early risk stratification has been based on clinical background factors, electrocardiography (ECG) and biochemical markers of myocardial damage. The neurohormonal activation has, so far, received less attention.
METHODS: The NT-proBNP was analyzed on admission in 755 patients admitted because of chest pain and no ST-segment elevation. Patients were followed concerning death for 40 months (median).
RESULTS: The median NT-proBNP level was 400 (111 to 1646) ng/l. Compared to the lowest quartile, patients in the second, third and fourth quartiles had a relative risk of subsequent death of 4.2 (1.6 to 11.1), 10.7 (4.2 to 26.8) and 26.6 (10.8 to 65.5), respectively. When NT-proBNP was added to a Cox regression model including clinical background factors, ECG and troponin T, the NT-proBNP levels were independently associated with prognosis.
CONCLUSIONS: A single measurement of NT-proBNP on admission will substantially improve the early risk stratification of patients with symptoms suggestive of an acute coronary syndrome and no ST-segment elevation. A combination of clinical background factors, ECG, troponin T and NT-proBNP obtained on admission will provide a highly discerning tool for risk stratification and further clinical decisions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142108     DOI: 10.1016/s0735-1097(02)01986-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  45 in total

1.  Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure.

Authors:  C Lüers; A Schmidt; R Wachter; F Fritzsche; A Sutcliffe; S Kleta; A Zapf; G Hagenah; L Binder; B Maisch; B Pieske
Journal:  Herz       Date:  2010-10       Impact factor: 1.443

2.  Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention.

Authors:  Hong-ying Liu; Wei Wang; Da-zhuo Shi; Jun-bo Ge; Lei Zhang; Juan Peng; Cheng-long Wang; Pei-li Wang
Journal:  Chin J Integr Med       Date:  2012-02-29       Impact factor: 1.978

3.  Transient elevation of NT-pro-BNP as a predictor for myocardial ischemia.

Authors:  Sebastian Szardien; Holger M Nef; Helge Möllmann; Sandra Voss; Christian Troidl; Christoph Liebetrau; Andreas Rolf; Johannes Rixe; Michael Weber; Christian W Hamm
Journal:  Clin Res Cardiol       Date:  2010-09-07       Impact factor: 5.460

Review 4.  Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes.

Authors:  Ankie Amos; L Kristin Newby
Journal:  Curr Cardiol Rep       Date:  2005-07       Impact factor: 2.931

5.  NT-proBNP is associated with SYNTAX score and aortic distensibility in patients with stable CAD.

Authors:  D Y Sahin; M Gür; Z Elbasan; N Y Koyunsever; C Türkoğlu; S Akyol; A Yıldırım; G Gözübüyük; B Ozaltun; M Caylı
Journal:  Herz       Date:  2013-03-14       Impact factor: 1.443

6.  Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery.

Authors:  Harm H H Feringa; Olaf Schouten; Martin Dunkelgrun; Jeroen J Bax; Eric Boersma; Abdou Elhendy; Robert de Jonge; Stefanos E Karagiannis; Radosav Vidakovic; Don Poldermans
Journal:  Heart       Date:  2006-08-16       Impact factor: 5.994

7.  A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.

Authors:  Gjin Ndrepepa; Siegmund Braun; Julinda Mehilli; Kathrin Niemöller; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2006-10-30       Impact factor: 5.460

8.  Biomarkers after risk stratification in acute chest pain (from the BRIC Study).

Authors:  Shiny Mathewkutty; Sanjum S Sethi; Ashish Aneja; Kshitij Shah; Rupa L Iyengar; Luke Hermann; Sayyar Khakimov; Louai Razzouk; Ricardo Esquitin; Rajesh Vedanthan; Terrie-Ann Benjamin; Marie Grace; Rosane Nisenbaum; Krishnan Ramanathan; Lakshmi Ramanathan; James Chesebro; Michael E Farkouh
Journal:  Am J Cardiol       Date:  2012-12-06       Impact factor: 2.778

Review 9.  Natriuretic peptide hormone measurement in acute coronary syndromes.

Authors:  Param Maewal; James A de Lemos
Journal:  Heart Fail Rev       Date:  2003-10       Impact factor: 4.214

10.  The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.

Authors:  Van Kimmenade
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.